Cavion announced Spyridon Papapetropoulos, former Teva vice president, has joined the clinical stage biopharma company as executive vice president of research and development as well as its chief medical officer. According to Cavion, Papapetropoulos will lead the R&D team in advancing therapies based on the company’s T-type calcium channel (Cav3) platform.
“[Papapetropoulos] joins the Cavion team at an exciting time,” said Cavion CEO and president Andrew Krouse. He is an experienced leader with a passion for conducting innovative trials that deliver new treatment options to patients with neurological diseases with limited treatment options.”
“Cavion’s selective Cav3 modulating platform, which includes best-in-class clinical stage compounds, is expected to restore rhythmic neuronal firing in brain regions associated with a variety of chronic neurological diseases,” Papapetropoulos said. I look forward to working closely with Cavion’s team to apply innovative but empathetic approaches to achieving clinical breakthroughs. Our end goal is to bring safe, effective and accessible treatments to people with chronic neurological diseases, quickly and efficiently.”
Papapetropoulos most recently served as vice president of global specialty development, neurodegenerative diseases, movement disorders and clinical trial innovation for Teva.
Read the press release